Please assess the completion status of the following clinical trial:

Trial Title: Study of Herbal Formula Corresponding to Syndrome in Treating Post Percutaneous Coronary Intervention (PCI) Patients With Coronary Heart Disease (CHD)

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: QUADRUPLE
- Phase: None
- Number of Arms: 3.0

Eligibility Criteria:
Inclusion Criteria:~* 18-75 years old~* Clinical diagnosis of coronary heart disease (confirmed by coronary angiography)~* Successfully received interventional therapy (PTCA or PCI)~* belong to TCM blood-stasis syndrome~* Must be able to swallow tablets~* Able to give written informed consent~Exclusion Criteria:~* Symptomatic congestive heart failure(New York Heart Association class III-IV)~* Females during pregnancy or lactation~* Serious dysfunction in important organs (liver, lung, kidney，et al)~* Use of concomitant Chinese herbal medicine~* Already attend other clinical trial

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: 75 Years
- Healthy Volunteers: f

Study Arms:
- Xuefu Zhuyu Capsules (Type: EXPERIMENTAL): None
- Sheng Mai Capsules (Type: ACTIVE_COMPARATOR): None
- Placebo (Type: PLACEBO_COMPARATOR): None

Based on this trial design, predict the completion outcome and termination type (if applicable).